269 related articles for article (PubMed ID: 23209191)
1. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Darsalia V; Ortsäter H; Olverling A; Darlöf E; Wolbert P; Nyström T; Klein T; Sjöholm Å; Patrone C
Diabetes; 2013 Apr; 62(4):1289-96. PubMed ID: 23209191
[TBL] [Abstract][Full Text] [Related]
2. DPP-4 inhibition and neuroprotection: do mechanisms matter?
Shannon RP
Diabetes; 2013 Apr; 62(4):1029-31. PubMed ID: 23520281
[No Abstract] [Full Text] [Related]
3. Diabetes: Add-on to metformin in T2DM--linagliptin or glimepiride?
Christensen M; Knop FK
Nat Rev Endocrinol; 2012 Oct; 8(10):576-8. PubMed ID: 22926098
[No Abstract] [Full Text] [Related]
4. Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Darsalia V; Olverling A; Larsson M; Mansouri S; Nathanson D; Nyström T; Klein T; Sjöholm Å; Patrone C
Regul Pept; 2014 May; 190-191():25-31. PubMed ID: 24821550
[TBL] [Abstract][Full Text] [Related]
5. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
[TBL] [Abstract][Full Text] [Related]
6. Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Forst T; Anastassiadis E; Diessel S; Löffler A; Pfützner A
Diabetes Metab Res Rev; 2014 Oct; 30(7):582-9. PubMed ID: 24459063
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Glycemia in the Recovery Phase After Stroke Counteracts the Detrimental Effect of Obesity-Induced Type 2 Diabetes on Neurological Recovery.
Augestad IL; Pintana H; Larsson M; Krizhanovskii C; Nyström T; Klein T; Darsalia V; Patrone C
Diabetes; 2020 Sep; 69(9):1961-1973. PubMed ID: 32540876
[TBL] [Abstract][Full Text] [Related]
8. Linagliptin as add-on therapy for type 2 diabetes - an overview.
Brown DX; Choudhury M; Evans M
Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
[TBL] [Abstract][Full Text] [Related]
9. Gliptin-mediated neuroprotection against stroke requires chronic pretreatment and is independent of glucagon-like peptide-1 receptor.
Darsalia V; Larsson M; Lietzau G; Nathanson D; Nyström T; Klein T; Patrone C
Diabetes Obes Metab; 2016 May; 18(5):537-41. PubMed ID: 26847506
[TBL] [Abstract][Full Text] [Related]
10. Linagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.
Toth PP
Postgrad Med; 2011 Jul; 123(4):46-53. PubMed ID: 21680988
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin and newer DPP-4 inhibitors: newer uses and newer indications.
Kalra S; Unnikrishnan AG; Agrawal N; Singh AK
Recent Pat Endocr Metab Immune Drug Discov; 2011 Sep; 5(3):197-202. PubMed ID: 21913883
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin: a novel xanthine-based dipeptidyl peptidase-4 inhibitor for treatment of type II diabetes mellitus.
Ghatak SB; Patel DS; Shanker N; Srivastava A; Deshpande SS; Panchal SJ
Curr Diabetes Rev; 2011 Sep; 7(5):325-35. PubMed ID: 21916836
[TBL] [Abstract][Full Text] [Related]
13. Postprandial renal haemodynamic effects of the dipeptidyl peptidase-4 inhibitor linagliptin versus the sulphonylurea glimepiride in adults with type 2 diabetes (RENALIS): A predefined substudy of a randomized, double-blind trial.
Muskiet MHA; Tonneijck L; Smits MM; Kramer MHH; Ouwens DM; Hartmann B; Holst JJ; Danser AHJ; Joles JA; van Raalte DH
Diabetes Obes Metab; 2022 Jan; 24(1):115-124. PubMed ID: 34580975
[TBL] [Abstract][Full Text] [Related]
14. Effects of dipeptidyl peptidase-4 inhibitor linagliptin versus sulphonylurea glimepiride on systemic haemodynamics in overweight patients with type 2 diabetes: A secondary analysis of an 8-week, randomized, controlled, double-blind trial.
Kraaijenhof J; Muskiet MHA; Tonneijck L; Ouwens DM; Kramer MHH; van Raalte DH; Smits MM
Diabetes Obes Metab; 2020 Oct; 22(10):1847-1856. PubMed ID: 32476255
[TBL] [Abstract][Full Text] [Related]
15. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes.
Tiwari A
Curr Opin Investig Drugs; 2009 Oct; 10(10):1091-104. PubMed ID: 19777398
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of the dipeptidyl peptidase-4 inhibitor linagliptin.
Grunberger G
Postgrad Med; 2013 May; 125(3):79-90. PubMed ID: 23748509
[TBL] [Abstract][Full Text] [Related]
17. Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy.
Barnett AH
Adv Ther; 2011 Jun; 28(6):447-59. PubMed ID: 21603986
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury.
Terawaki Y; Nomiyama T; Kawanami T; Hamaguchi Y; Takahashi H; Tanaka T; Murase K; Nagaishi R; Tanabe M; Yanase T
Cardiovasc Diabetol; 2014 Nov; 13():154. PubMed ID: 25407968
[TBL] [Abstract][Full Text] [Related]
19. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.
Kern M; Klöting N; Niessen HG; Thomas L; Stiller D; Mark M; Klein T; Blüher M
PLoS One; 2012; 7(6):e38744. PubMed ID: 22761701
[TBL] [Abstract][Full Text] [Related]
20. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
